TLR4 Agonist Compounds for Broad PGN Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies fail to fully understand the biological functions of gut microbiota-derived peptidoglycan fragments (PGNs) and their potential to modulate immune responses, limiting the development of compounds that can promote gastrointestinal health and treat inflammatory bowel diseases.
Innovation Solution
Development of Toll-Like Receptor 4 (TLR4) agonists, such as synthetic peptidoglycan derivatives, which stimulate immune responses independently of NOD1/2 receptors, and their use in compositions and probiotics to modulate gut microbiota and treat gastrointestinal diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NOD1/2 receptor ligands are used to stimulate immune response, then immune activation is achieved, but the diversity of gut microbiota-derived PGN structures cannot be fully captured
Solution Approach 1:
The patent changes the molecular parameters of PGN ligands by creating synthetic analogs with modified chemical structures (different sugar moieties, peptide configurations, and glycan chains) that can bind to both NOD1/2 and TLR4 receptors, thereby expanding the range of detectable PGN structures while maintaining reliable immune activation
Solution Approach 2:
The patent develops universal PGN ligands that can simultaneously engage multiple receptor types (NOD1, NOD2, and TLR4), allowing a single compound class to stimulate immune responses across diverse microbial structures rather than requiring separate ligands for each receptor pathway
2Measurement precision
If traditional cell-based reporter assays are used to detect PGNs, then NOD1/2 ligand detection is achieved, but non-canonical PGN motifs remain undetected
Solution Approach 1:
The patent introduces TLR4 as an intermediary receptor that can be activated by a broader spectrum of PGN structures. By using TLR4 as a secondary detection pathway alongside NOD1/2, the system can detect non-canonical PGN motifs that would otherwise remain invisible to traditional assays
Solution Approach 2:
The patent creates composite detection systems that combine multiple receptor-specific ligands (NOD1, NOD2, and TLR4 agonists) into a unified assay platform, enabling simultaneous detection of diverse PGN structures through a single integrated measurement system
3Reliability
If monosaccharide PGNs are used as TLR4 ligands, then TLR4 activation is achieved, but the complex heterogeneous peptidoglycome structure is oversimplified
Solution Approach 1:
The patent segments the complex peptidoglycome structure into functional modular units (different sugar moieties, peptide configurations, and glycan chain lengths) that can be independently synthesized and tested, allowing systematic exploration of structure-activity relationships while maintaining TLR4 activation
Solution Approach 2:
The patent applies local quality modifications to specific regions of the PGN molecules (such as varying the peptide stem sequence or glycan chain composition at different positions) to create a library of ligands with distinct binding characteristics while maintaining overall TLR4 activation capability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The TLR4 agonists effectively stimulate immune responses and promote gastrointestinal health, providing therapeutic benefits for conditions like inflammatory bowel disease by modulating gut microbiota and reducing inflammation.
Implementation Method 1
compounds that exhibit Toll-like receptor 4 (TLR4) agonist activity... capable of stimulating or promoting a TLR4-mediated immune response
Data Source
AI summary
The present invention relates generally to the field of immunomodulation and more specifically to compounds that exhibit Toll-like receptor 4 (TLR4) agonist activity. The invention provides novel compounds capable of stimulating or promoting an immune response, thereby offering potential therapeutic applications. In particular, the compounds may be useful in methods of promoting and/or maintain gastrointestinal health, as well as treating or preventing gastrointestinal diseases, such as IBD and colitis.